The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Clearing 19 biologics for Europe market
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Study will assess the safety and effectiveness of irreversible electroporation as a minimally invasive treatment option for benign prostatic hyperplasia (BPH)
New-generation cardiac ablation technology expands treatment options for atrial fibrillation patients, offering a non-thermal approach to improve safety and procedural efficiency
Preclinical CRO strengthens leadership team with key executive appointments as it scales its human tissue-based drug discovery platform
The company will present 21 oral and poster presentations spanning investigational and approved therapies
New platform integrates advanced cardiac mapping and ablation workflow, offering a novel treatment option for AFib patients at risk of stroke and heart failure
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
